Latest Regulatory Approvals News

Botanix Pharmaceuticals has launched a A$45 million capital raising to support the expansion of its dermatology product Sofdra®, while negotiating to reduce active pharmaceutical ingredient costs by up to 40%. The raising includes a two-tranche placement and a security purchase plan, with options offered to investors.

EAU Lithium, backed by Cosmos Exploration, has formalised a negotiation framework with Bolivia’s state lithium company YLB to explore industrial-scale lithium extraction using Vulcan Energy’s innovative technology.

Medallion Metals has secured a US$50 million loan and a copper-gold concentrate offtake agreement with Trafigura, enabling the Final Investment Decision for the Ravensthorpe Gold Project. Development is set to begin pending completion of the Forrestania acquisition.

Black Canyon Limited (ASX, BCA) has unveiled promising exploration results and positive scoping studies for its manganese and iron projects in Western Australia, positioning itself as a key emerging developer in the sector.

Tetratherix Limited reveals promising interim results for TetraDerm, its scar prevention product, showing minimal scarring in patients after skin lesion surgeries. The product’s unique approach could reshape wound closure in a $US2.1 billion market.

Adavale Resources has secured adjacent exploration licences from Alkane Resources, boosting its Parkes Gold-Copper Project footprint and strengthening its position along a key gold corridor in New South Wales.

Prominence Energy has begun preparatory work for its first geochemical survey in South Australia's PEL 803, aiming to detect natural hydrogen and helium as part of the Gawler Hydrogen Project.

Lunnon Metals reports robust drilling results at Lady Herial, confirming significant high-grade gold mineralisation beyond current open pit plans and signalling potential for an expanded mining footprint.

Challenger reports a solid first half of FY26 with rising profits, strong annuity sales, and strategic partnerships, underpinning a confident outlook and a $150 million share buy-back plan.

Qube Holdings has inked a scheme implementation deed with a Macquarie Asset Management-led consortium, valuing the company at approximately $11.7 billion and offering shareholders a 27.8% premium. The deal, subject to regulatory and shareholder approvals, sets the stage for a significant shift in the Australian logistics landscape.

Clarity Pharmaceuticals’ Cu-64 SAR-bisPSMA diagnostic agent significantly outperformed the current standard Ga-68 PSMA-11 in detecting prostate cancer recurrence, more than doubling lesion and patient detection rates in a pivotal head-to-head trial.

Red Mountain Mining has initiated metallurgical test work on high-grade samples from its Oaky Creek Antimony Prospect, advancing the Armidale Antimony-Gold Project towards commercial validation. This move aims to de-risk the asset ahead of drilling and capitalise on strong early exploration results.